Qilubevacizumab injection Shandong Guawang announces pricing

[December 16, 2019 / list of medical information] the evaluation of consumables consistency has broken the bidding and procurement pattern of "only the lowest bidder wins the bid", the first AI + single cell technology company has been informed of the famous venture capital flagship investment, and the first class new drug suofantini of Huang pharmaceutical has been given priority review Daily fresh medicine news, quick reading club and you pay attention Recently, according to the official website of the State Council, since the launch of the pilot project of centralized procurement and use by the state organization, the overall situation has been stable and orderly, which has strongly promoted the return of prices to a reasonable level In the field of medical devices, the State Council pointed out that to deepen the joint reform of medical treatment, medical insurance and medicine, all localities should learn from the experience of "Sanming medical reform", carry out the joint limited price purchase of medical consumables, and adjust according to the total amount control, structure, increase or decrease At the same time, it will improve management efficiency, cooperate with relevant management departments to establish a "consumables consistency evaluation organization", strengthen relevant research, improve the evaluation mechanism, and indirectly promote the reasonable control of the cost growth of disposable non implanted high-value consumables (State Council) On December 13, Jiangxi Medical Security Bureau and Jiangxi health and Health Commission jointly issued the notice on the results of the selection of the pilot areas for the implementation of centralized drug purchase and use organized by the state It was decided that from 0:00 on December 20, all public medical and health institutions in the province should implement the results of "4 + 7" nationwide expansion, and the grass-roots medical and health institutions, including township hospitals, should be implemented by December 2019 at the latest The results of the election will be fully implemented on May 25 (Jiangxi Medical Insurance Bureau, Jiangxi health and Health Commission) On the 14th, Guangxi Medical Insurance Bureau released information to carry out centralized volume purchase of drugs In addition to 25 varieties of 4 + 7, another 23 varieties were selected to be included in the volume purchase, and the implementation began a week later (Guangxi Medical Insurance Bureau) Recently, Shuangcheng pharmaceutical industry disclosed that it plans to sell the company's rights related to bevaludine for injection for 50 million yuan This transaction is expected to increase the company's profits by about 37.5 million yuan, which has a great impact on the net profits attributable to shareholders of Listed Companies in 2019 (meter net) Flagship pioneer, a famous biomedical venture capital organization, invested 50 million US dollars for its incubated cellular company to help it develop a pioneering biotechnology platform for targeting cell-based behavioral drugs The platform uses single cell technology, artificial intelligence and other technologies to study cell behavior at the same time, which has considerable development potential It is said that it can cover 99% of the drug development field! (chuangjianhui) Johnson & Johnson's Janssen Pharmaceutical recently announced that the EMA human pharmaceutical products committee has issued a positive review opinion, recommending and approving the existing marketing authorization of darzalex, including: the combination of bortezomib, thalidomide and dexamethasone, the first-line treatment of patients with newly diagnosed multiple myeloma who meet the conditions of autologous stem cell transplantation The CHMP's comments will now be reviewed by the European Commission, which expects a final approval decision in the coming months (Biovalley) On April 14, Shandong provincial centralized drug purchase platform issued notice on the publication of the online publication of bevacizumab injection, a biological similar drug, and announced the publication of the online publication of bevacizumab injection (specification: 4ml: 0.1g) produced by Qilu Pharmaceutical Co., Ltd., with the proposed online price of 1266 yuan / bottle (medicine cube) Aosaikang announced that Jiangsu aosaikang Pharmaceutical Co., Ltd., a subsidiary of aosaikang, signed a letter of intent with Shanghai xuantai pharmaceutical technology Shanghai xuantai intends to authorize Jiangsu aosaikang with the exclusive promotion, commercial and agent sales rights and interests of posaconazole enteric coated tablets in mainland China Posaconazole enteric coated tablets of xuantai have been listed and sold in the United States on August 21, 2019, reported for production in China on February 19, 2019, and entered the priority review list on September 16, 2019 It is the first one to complete the bioequivalence test in China It is expected that posaconazole enteric coated tablets will be successfully listed in 2020 (meter net) Novo Nordisk submitted five clinical applications for its sugar lowering drug semaglutide injection at one time, the official CDE website said Tuesday Somaluptide is a heavy-duty GLP-1 receptor agonist As one of the most important markets of the company's global hypoglycemic drug business, Novo Nordisk aims to accelerate the listing of somaluptide in China through domestic registered research (CPHI Pharma online) Recently, the clinical application of absk-011 capsule submitted by Heyu biology was accepted by CDE Previously, Taiwan's food and Drug Administration (TFDA) has allowed the drug to carry out phase I clinical research on HCC Absk-011 is an innovative FGFR4 small molecule oral inhibitor independently developed by Heyu pharmaceutical and with global intellectual property rights It has been found that FGFR4 signaling pathway is often overactivated in liver cancer Therefore, by inhibiting the activity of FGFR4 and blocking the related signaling pathway, tumor growth can be inhibited (medicine cube) The listing application of suofentini, a new drug of Hehuang pharmaceutical, is proposed to be included in the priority review by CDE Sofantini is the second class 1 new drug independently developed and applied for market by Hehuang pharmaceutical after furaquini Sofantini is the first innovative drug in China to terminate clinical trials in advance due to its good curative effect It is used to treat advanced non pancreatic neuroendocrine tumors, opening the era of targeted treatment of non pancreatic neuroendocrine tumors in China (CPHI Pharma online) Recently, Lilly announced that the EMA Committee on human pharmaceutical products recommended the EU to approve a combination therapy composed of cyramza, an anti angiogenic monoclonal antibody, and erlotinib, a tyrosine kinase inhibitor, for the first-line treatment of adult patients with metastatic non-small cell lung cancer with EGFR gene mutation (yaomingkant) Recently, the CDE official website showed that another class 1 new drug of Hengrui, shr5126, was accepted At present, there is not much information disclosed by Hengrui about shr5126 The only clear thing is that it is an adenosine receptor A2AR inhibitor (CPHI Pharma online) Gritstone oncology announced at the ESMO IO conference that its two vaccines, granite and slate, based on new tumor antigens, obtained positive immunogenic activity and safety data in phase 1 clinical trials The preliminary results obtained in the low dose group showed that the two vaccines not only had good tolerance and safety, but also could activate new antigen-specific CD8 positive T cells rapidly and stably, and expand the existing T cells (yaomingkant) Novartis, a Swiss pharmaceutical giant, recently announced that the EMA human pharmaceutical products committee has issued a positive review opinion, recommending the approval of a new generation of ophthalmic drug beovu for the treatment of wet age-related macular degeneration The CHMP's comments will now be reviewed by the European Commission, which expects to make a final approval decision within the next three months (Biovalley) Genentech, a subsidiary of Roche, announced at the SABCS meeting that the latest data of Federica, a phase III clinical study on the treatment of HER2 + early breast cancer with perjeta + Herceptin fixed dose combined subcutaneous injection and chemotherapy, were compared with that of perjeta, a standard intravenous injection+ Compared with Herceptin combined chemotherapy, the former has similar efficacy and safety, and the level of perjeta in blood also shows non inferiority, reaching the main end point (CPHI Pharma online) Horizon therapeutics announced that the FDA advisory committee on skin and ophthalmic drugs fully supports the use of the company's humanized monoclonal antibody teprotumumab in the treatment of thyroid ophthalmopathy If approved, teprotumumab will be the only approved treatment for Ted patients and will meet significant unmet medical needs (yaomingkant) Recently, researchers at the University of Texas Houston Health Science Center found that the secret weapon of super bacteria with high resistance is a special protein that can make it resistant to antibiotic treatment and the attack of the body's immune system The results of this study were published in PNAS As a magic weapon to win VRE, the mystery of this protein has been gradually revealed This discovery provides a new idea for the future treatment of antibiotic resistance (biological exploration)